Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Free Report) - Stock analysts at Atb Cap Markets issued their Q3 2025 earnings per share (EPS) estimates for Curaleaf in a research note issued on Tuesday, March 4th. Atb Cap Markets analyst F. Gomes anticipates that the company will earn ($0.05) per share for the quarter. The consensus estimate for Curaleaf's current full-year earnings is ($0.25) per share. Atb Cap Markets also issued estimates for Curaleaf's Q4 2025 earnings at ($0.05) EPS.
Separately, Roth Capital raised shares of Curaleaf to a "strong-buy" rating in a report on Sunday, November 10th.
View Our Latest Stock Report on Curaleaf
Curaleaf Stock Down 2.0 %
OTCMKTS CURLF traded down $0.02 during trading on Thursday, reaching $0.99. 985,502 shares of the company's stock traded hands, compared to its average volume of 748,980. Curaleaf has a 12-month low of $0.88 and a 12-month high of $6.40. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.11 and a quick ratio of 0.51. The firm has a market cap of $654.02 million, a price-to-earnings ratio of -3.41 and a beta of 0.57. The company's 50 day simple moving average is $1.41 and its two-hundred day simple moving average is $2.13.
Curaleaf (OTCMKTS:CURLF - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.07) by $0.09. The firm had revenue of $331.05 million for the quarter, compared to analyst estimates of $331.87 million. Curaleaf had a negative return on equity of 13.67% and a negative net margin of 14.82%.
About Curaleaf
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Featured Articles
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
